NOA-12: BIBF1120 and R-RT in Glioblastoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
Patients with glioblastoma at first or second progression who have failed standard treatment that must have included radiochemotherapy with temozolomide and who are a candidate for a reirradiation can be included into the trial. In the phase I part the minimal tolerated dose (MTD)of BIBF 1120 in combination with radiotherapy will be investigated. Subjects in phase II will be randomised to receive reirradiation alone or reirradiation + 2 x MTD BIBF1120.
Epistemonikos ID: 22772eb9dae1f70857c757b4c72b2759b9343970
First added on: May 11, 2024